← Leaderboards
Shiu-Lok Hu
University Of Washington
$65,602,557
Attributed
$65,602,557
Total exposure
68
Grants
48
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $6.2M · FY2005–21$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$73,225,454 · 69
By mechanism
P01$29,641,571 · 7
P51$19,748,613 · 55
R01$15,611,858 · 5
U19$8,223,412 · 2
Top collaborators
No co-investigators on record.
Most similar at University Of Washington
Same institution · by research overlap
- Juan Bonifacino$3,443
- David M Anderson$21,829,168
- Charlotte Hotchkiss$10,673,162
- Marjorie Robert-Guroff$2,142,617
- Murali-Krishna Kaja$5,864,916
Others in their field
Top investigators on “Macaca”
- Barton F Haynes · Duke University$291,402,363
- Peter Gordon Gillespie · Oregon Health And Science University$96,229,141
- Richard A Gibbs · Baylor College Of Medicine$82,807,896
- Dennis R. Burton · Scripps Research Institute$75,153,374
- Larry S. Schlesinger · Texas Biomedical Research Institute$72,536,876
- Dan H. Barouch · Fred Hutchinson Cancer Center$68,546,715
Research focus
MacacaVirusHiv-1InfectionSimian Human Immunodeficiency VirusResourcesVaccinesNeutralizing AntibodyFundingImmunizationGrantResearch PersonnelUnited States National Institutes Of HealthAntigensPrimatesSourceViralAnimalsIn VivoResponseVaccine DevelopmentAids VaccinesAntibodiesImmunity
Grant awards (120)
Approaches to Improve the Efficacy of Prime-boost Immunization against HIV/AIDS$891,161
R01 · FY2021 · AI · contact PI
VIRUS-LIKE PARTICLES WITH STABILIZED TRIMERIC ENVELOPE FOR PRIME BOOST IMMUNIZATION$900,802
R01 · FY2020 · AI · contact PI
Approaches to Improve the Efficacy of Prime-boost Immunization against HIV/AIDS$891,161
R01 · FY2020 · AI · contact PI
Approaches to Improve the Efficacy of Prime-boost Immunization against HIV/AIDS$891,161
R01 · FY2019 · AI · contact PI
VIRUS-LIKE PARTICLES WITH STABILIZED TRIMERIC ENVELOPE FOR PRIME BOOST IMMUNIZATION$615,347
R01 · FY2019 · AI · contact PI
NHP Model and Transplantation Core$485,926
U19 · FY2019 · HL · contact PI
Approaches to Improve the Efficacy of Prime-boost Immunization against HIV/AIDS$875,225
R01 · FY2018 · AI · contact PI
VIRUS-LIKE PARTICLES WITH STABILIZED TRIMERIC ENVELOPE FOR PRIME BOOST IMMUNIZATION$615,347
R01 · FY2018 · AI · contact PI
NHP Model and Transplantation Core$485,926
U19 · FY2018 · HL · contact PI
Approaches to Improve the Efficacy of Prime-boost Immunization against HIV/AIDS$874,640
R01 · FY2017 · AI · contact PI
VIRUS-LIKE PARTICLES WITH STABILIZED TRIMERIC ENVELOPE FOR PRIME BOOST IMMUNIZATION$614,889
R01 · FY2017 · AI · contact PI
NHP Model and Transplantation Core$485,926
U19 · FY2017 · HL · contact PI
AIDS Research Division$443,434
P51 · FY2017 · OD · contact PI
AIDS Virology$443,434
P51 · FY2017 · OD · contact PI
NHP Model and Transplantation Core$485,926
U19 · FY2016 · HL · contact PI
Nonhuman Primate Core$1,316,048
U19 · FY2015 · AI · contact PI
Oral immunization against HIV/AIDS with prime-boost strategies$604,562
R01 · FY2015 · DE · contact PI
NHP Model and Transplantation Core$502,133
U19 · FY2015 · HL · contact PI
Nonhuman Primate Core$1,092,245
U19 · FY2014 · AI · contact PI
Strategies for inducing bnAbs against QNES by infection with SHIVs$786,836
P01 · FY2014 · AI · contact PI
Oral immunization against HIV/AIDS with prime-boost strategies$764,999
R01 · FY2014 · DE · contact PI
Strategies for inducing bnAbs against QNES by infection with SHIVs$1,281,787
P01 · FY2013 · AI · contact PI
Nonhuman Primate Core$1,264,865
U19 · FY2013 · AI · contact PI
Oral immunization against HIV/AIDS with prime-boost strategies$692,038
R01 · FY2013 · DE · contact PI
Strategies for inducing bnAbs against QNES by infection with SHIVs$116,169
P01 · FY2013 · AI · contact PI
Nonhuman Primate Core$1,019,620
U19 · FY2012 · AI · contact PI
Strategies for inducing bnAbs against QNES by infection with SHIVs$909,236
P01 · FY2012 · AI · contact PI
Oral immunization against HIV/AIDS with prime-boost strategies$489,040
R01 · FY2012 · DE · contact PI
Nonhuman Primate Core$1,084,797
U19 · FY2011 · AI · contact PI
Strategies for inducing bnAbs against QNES by infection with SHIVs$833,435
P01 · FY2011 · AI · contact PI
Glycan modification, CD4 independence, and Env immunogenicity$824,905
R01 · FY2011 · AI · contact PI
Oral immunization against HIV/AIDS with prime-boost strategies$538,136
R01 · FY2011 · DE · contact PI
ORIGIN AND EVOLUTION OF HIV-1 DRUG RESISTANCE$377,899
P51 · FY2011 · RR · contact PI
INFECTIVITY OF HSIV-VIF CHIMERA IN NEWBORN PIGTAILED MACAQUES$377,899
P51 · FY2011 · RR · contact PI
INFECTIVITY OF HSIV-VIF CHIMERA IN PIGTAILED MACAQUES$377,899
P51 · FY2011 · RR · contact PI
COMBINED APPROACH TO BROADLY PROTECTIVE AIDS VACCINES: PROJECT 4$377,899
P51 · FY2011 · RR · contact PI
PROTECTIVE EFFICACY OF GLYCAN-MODIFIED ENV VACCINE$377,899
P51 · FY2011 · RR · contact PI
IMMUNOPATHOGENESIS OF CLADE C SHIV-1157IPD3N4 IN M NEMESTRINA$377,899
P51 · FY2011 · RR · contact PI
Recombinant Protein Immunogens$336,501
P01 · FY2011 · AI · contact PI
INTRARECTAL TITRATION OF SHIV 162P4 STOCK$328,590
P51 · FY2011 · RR · contact PI
Glycan modification, CD4 independence, and Env immunogenicity$839,486
R01 · FY2010 · AI · contact PI
Strategies for inducing bnAbs against QNES by infection with SHIVs$617,024
P01 · FY2010 · AI · contact PI
INFECTIVITY OF HSIV-VIF CHIMERA IN PIGTAILED MACAQUES$465,257
P51 · FY2010 · RR · contact PI
COMBINED APPROACH TO BROADLY PROTECTIVE AIDS VACCINES: PROJECT 4$465,257
P51 · FY2010 · RR · contact PI
EFFICACY OF GLYCAN-MODIFIED ENV VACCINES AGAINST HETEROLOGOUS SHIV CHALLENGE$465,257
P51 · FY2010 · RR · contact PI
COMBINED APPROACH TO BROADLY PROTECTIVE AIDS VACCINES: CORE B$465,257
P51 · FY2010 · RR · contact PI
IMMUNOPATHOGENESIS OF CLADE C SHIV-1157IPD3N4 IN M NEMESTRINA$465,257
P51 · FY2010 · RR · contact PI
INTRARECTAL TITRATION OF SHIV 162P4 STOCK$465,257
P51 · FY2010 · RR · contact PI
INFECTIVITY OF HSIV-VIF CHIMERA IN NEWBORN PIGTAILED MACAQUES$465,257
P51 · FY2010 · RR · contact PI
Recombinant Protein Immunogens$287,935
P01 · FY2010 · AI · contact PI
Glycan modification, CD4 independence, and Env immunogenicity$731,320
R01 · FY2009 · AI · contact PI
INTRARECTAL TITRATION OF SHIV 162P4 STOCK$497,090
P51 · FY2009 · RR · contact PI
Recombinant Protein Immunogens$350,135
P01 · FY2009 · AI · contact PI
COMBINED APPROACH TO BROADLY PROTECTIVE AIDS VACCINES: PROJECT 4$331,394
P51 · FY2009 · RR · contact PI
INFECTIVITY OF HSIV-VIF CHIMERA IN PIGTAILED MACAQUES$331,394
P51 · FY2009 · RR · contact PI
EFFICACY OF GLYCAN-MODIFIED ENV VACCINES AGAINST HETEROLOGOUS SHIV CHALLENGE$331,393
P51 · FY2009 · RR · contact PI
COMBINED APPROACH TO BROADLY PROTECTIVE AIDS VACCINES: CORE B$331,393
P51 · FY2009 · RR · contact PI
IMMUNOPATHOGENESIS OF CLADE C SHIV-1157IPD3N4 IN M NEMESTRINA$331,393
P51 · FY2009 · RR · contact PI
Glycan modification, CD4 independence, and Env immunogenicity$565,469
R01 · FY2008 · AI · contact PI
COMBINED APPROACH TO BROADLY PROTECTIVE AIDS VACCINES: II$422,135
P51 · FY2008 · RR · contact PI
COMBINED APPROACH TO BROADLY PROTECTIVE AIDS VACCINES: I$422,135
P51 · FY2008 · RR · contact PI
INTRARECTAL TITRATION OF SHIV 162P4 STOCK$422,135
P51 · FY2008 · RR · contact PI
Recombinant Protein Immunogens$268,215
P01 · FY2008 · AI · contact PI
Combined Approach to Broadly Protective AIDS Vaccines$3,047,144
P01 · FY2007 · AI · contact PI
COMBINED APPROACH TO BROADLY PROTECTIVE AIDS VACCINES: I$434,135
P51 · FY2007 · RR · contact PI
DETERMINANTS OF VACCINE PROTECTION IN AN SIV MODEL$434,135
P51 · FY2007 · RR · contact PI
COMBINED APPROACH TO BROADLY PROTECTIVE AIDS VACCINES: II$434,134
P51 · FY2007 · RR · contact PI
DEVELOPMENT OF A RT-SHIVMNE MODEL$434,134
P51 · FY2007 · RR · contact PI
INTRARECTAL TITRATION OF SHIV 162P4 STOCK$434,134
P51 · FY2007 · RR · contact PI
Recombinant Protein Immunogens$269,919
P01 · FY2007 · AI · contact PI
Combined Approach to Broadly Protective AIDS Vaccines$3,431,489
P01 · FY2006 · AI · contact PI
COMPARISON OF RECOMBINANT VACCINIA AND ALDRITHIOL-2 INACTIVATED SIV VACCINES$293,779
P51 · FY2006 · RR · contact PI
DETERMINANTS OF VACCINE PROTECTION IN AN SIV MODEL$293,779
P51 · FY2006 · RR · contact PI
INTRARECTAL TITRATION OF SHIV 162P4 STOCK$228,467
P51 · FY2006 · RR · contact PI
COMBINED APPROACH TO BROADLY PROTECTIVE AIDS VACCINES: II$228,467
P51 · FY2006 · RR · contact PI
DEVELOPMENT OF A RT-SHIVMNE MODEL$228,467
P51 · FY2006 · RR · contact PI
IMMUNOGENICITY OF ENV AND/OR CORE ANTIGENS OF HIV-1$228,467
P51 · FY2006 · RR · contact PI
COMBINED APPROACH TO BROADLY PROTECTIVE AIDS VACCINES: I$228,467
P51 · FY2006 · RR · contact PI
IN VIVO EVALUATION OF PRIMATE LENTIVIRUSES$228,467
P51 · FY2006 · RR · contact PI
Combined Approach to Broadly Protective AIDS Vaccines$3,748,460
P01 · FY2005 · AI
DETERMINANTS OF VACCINE PROTECTION IN A SIV MODEL$440,546
R01 · FY2005 · AI
DIVISION OF AIDS-RELATED RESEARCH$249,042
P51 · FY2005 · RR
IMMUNOGENICITY OF ENV AND/OR CORE ANTIGENS OF HIV-1: II$175,831
P51 · FY2005 · RR
COMPARISON OF RECOMBINANT VACCINIA AND ALDRITHIOL-2 INACTIVATED SIV VACCINES: I$175,831
P51 · FY2005 · RR
DETERMINANTS OF VACCINE PROTECTION IN AN SIV MODEL$175,831
P51 · FY2005 · RR
IMMUNOGENICITY OF ENV AND/OR CORE ANTIGENS OF HIV-1: I$175,831
P51 · FY2005 · RR
COMPARISON OF RECOMBINANT VACCINIA AND ALDRITHIOL-2 INACTIVATED SIV VACCINES: II$175,831
P51 · FY2005 · RR
COMBINED APPROACH TO BROADLY PROTECTIVE AIDS VACCINES$175,831
P51 · FY2005 · RR
Combined Approach to Broadly Protective AIDS Vaccines$3,520,936
P01 · FY2004 · AI
COMPARISON OF RECOMBINANT VACCINIA AND SIV VACCINES$228,544
P51 · FY2004 · RR
IMMUNOGENICITY OF ENV AND/OR CORE ANTIGENS OF HIV-1$228,544
P51 · FY2004 · RR
COMPARISON OF RECOMBINANT VACCINIA AND SIV VACCINES$228,544
P51 · FY2004 · RR
DETERMINANTS OF VACCINE PROTECTION IN AN SIV MODEL$228,544
P51 · FY2004 · RR
DIVISION OF AIDS-RELATED RESEARCH$228,544
P51 · FY2004 · RR
IMMUNOGENICITY OF ENV AND/OR CORE ANTIGENS OF HIV-1$134,416
P51 · FY2004 · RR
DETERMINANTS OF VACCINE PROTECTION IN A SIV MODEL$1
R01 · FY2004 · AI
DIVISION OF AIDS-RELATED RESEARCH$1,609,414
P51 · FY2003 · RR
Combined Approach to Broadly Protective AIDS Vaccines$1,355,705
P01 · FY2003 · AI
DETERMINANTS OF VACCINE PROTECTION IN A SIV MODEL$477,040
R01 · FY2003 · AI
IN VIVO INFECTIVITY AND PATHOGENICITY OF MOLECULAR CLONES OF HIV-2/287$189,414
P51 · FY2003 · RR
ROLE OF CD8 T CELL IN THE CONTROL OF HIV-2 INFECTION$189,414
P51 · FY2003 · RR
IMMUNITY AGAINST DIFFERENT SIV CHALLENGE CONDITIONS$189,414
P51 · FY2003 · RR
IMMUNOGENICITY OF ENV AND/OR CORE ANTIGENS OF HIV$189,414
P51 · FY2003 · RR
COMPARISON OF RECOMBINANT VACCINIA AND ALDRITHIOL-2 INACTIVATED SIV VACCINES$189,414
P51 · FY2003 · RR
IN VIVO EVALUATION OF PRIMATE LENTIVIRUSES$189,414
P51 · FY2003 · RR
COMBINATION IMMUNIZATION AS AN APPROACH TO AIDS VACCINES$2,601,846
P01 · FY2002 · AI
DETERMINANTS OF VACCINE PROTECTION IN A SIV MODEL$475,424
R01 · FY2002 · AI
Core--HIV clade C env immunogen facility$171,466
P01 · FY2002 · AI
COMBINATION IMMUNIZATION AGAINST SHIV WITH ENVELOPE FROM PRIMARY HIV 1 ISOLATES$0
P01 · FY2002 · AI
COMBINATION IMMUNIZATION AS AN APPROACH TO AIDS VACCINES$2,545,773
P01 · FY2001 · AI
DETERMINANTS OF VACCINE PROTECTION IN A SIV MODEL$534,125
R01 · FY2001 · AI
Core--HIV clade C env immunogen facility$171,466
P01 · FY2001 · AI
COMBINATION IMMUNIZATION AGAINST SHIV WITH ENVELOPE FROM PRIMARY HIV 1 ISOLATES$0
P01 · FY2001 · AI
DEPLETION OF CD8+ CELLS IN HIV 2 INFECTED MACAQUES PREVIOUSLY TREATED W/ D4T$0
P51 · FY2001 · RR
IN VIVO INFECTIVITY &PATHOGENICITY OF MOLECULAR CLONES OF HIV 2287$0
P51 · FY2001 · RR
COMBINATION IMMUNIZATION AS AN APPROACH TO AIDS VACCINES$2,475,278
P01 · FY2000 · AI
DETERMINANTS OF VACCINE PROTECTION IN A SIV MODEL$465,034
R01 · FY2000 · AI
COMBINATION IMMUNIZATION AGAINST SHIV WITH ENVELOPE FROM PRIMARY HIV 1 ISOLATES$343,350
P01 · FY2000 · AI
Core--HIV clade C env immunogen facility$171,466
P01 · FY2000 · AI
RECOMBINANT VACCINIA VIRUSES EXPRESSING ENV AND/OR CORE ANTIGENS OF SIVMNE$132,406
P51 · FY2000 · RR